|
Clinical characteristics of endometriosis subjects. |
|||||
| Endometriosis Patients |
|||||
|
|
|||||
| Case reference |
Age (yr) |
AFS stage |
Sites of endometriotic lesions |
Gravidity |
Parity |
|
|
|||||
| 1*# |
40 |
II |
Peritoneal |
6 |
4 |
| 2*# |
28 |
I |
Uterosacral |
0 |
0 |
| 3*# |
28 |
II |
Peritoneal, Uterosacral |
0 |
0 |
| 4* |
29 |
II |
Peritoneal, Uterosacral |
0 |
0 |
| 5 |
27 |
V |
Uterosacral |
0 |
0 |
| 6 |
37 |
V |
Ovarian |
1 |
1 |
| 7 |
28 |
V |
Ovarian, Uterosacral, Pouch of Douglas |
1 |
0 |
| 8 |
35 |
III |
Ovarian |
1 |
1 |
| 9 |
37 |
IV |
Peritoneal |
0 |
0 |
| 10 |
37 |
II |
Peritoneal |
7 |
4 |
|
|
|||||
| Control Subjects |
|||||
|
|
|||||
| Case reference |
Age (yr) |
AFS stage |
Sites of endometriotic lesions |
Gravidity |
Parity |
|
|
|||||
| 1*# |
42 |
0 |
- |
0 |
0 |
| 2*# |
46 |
0 |
- |
3 |
3 |
| 3*# |
30 |
0 |
- |
4 |
2 |
| 4* |
32 |
0 |
- |
0 |
0 |
|
AFS, American Fertility Society *used in cDNA array analysis (amplified RNA) # used in real-time PCR analysis (unamplified RNA) | |||||
Chand et al. Reproductive Biology and Endocrinology 2007 5:18 doi:10.1186/1477-7827-5-18 |
|||||